Southern Archipelago (A33) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
5 Nov, 2026Executive summary
FY2025 revenue fell 17.8% YoY to S$3.96m and net loss widened to S$934,155 from S$152,723, amid Indonesian demand and competition headwinds and a one-off liquidation loss.
Major sterilisation facility upgrades were completed and operational by year-end; the 2026 priority is higher utilisation and restoring profitability.
Financial highlights
Revenue was S$3.961m versus S$4.817m in FY2024; total expenses were S$4.779m versus S$4.865m.
Loss before tax was S$736,332 versus prior-year profit of S$235,529; income tax expense was S$197,823 and net loss was S$934,155.
Other gains, net, declined to S$80,083 from S$272,015; included S$828,412 liquidation loss, partly offset by S$819,229 currency exchange gain.
Operating cash flow was S$820,485, investing outflow S$2.399m and financing inflow S$1.533m; cash ended at S$341,575.
Outlook and guidance
2026 focus shifts from heavy capex to operational ramp-up, higher utilisation at PT Rel-ion and restoration of profitability.
Near-term growth efforts centre on securing new sterilisation customers and increasing revenue following the completed capacity expansion.
Investment opportunities remain under review, while hospitality acquisitions stay paused pending stronger balance-sheet health and favourable conditions.
Latest events from Southern Archipelago
- Sterilisation recovery continues, but liquidity strains and a covenant breach cloud the outlook.A33
Q3 2026 - Revenue and net profit improved, but liquidity and diversification remain key challenges.A33
H2 2023 - A return to modest profit meets weaker revenue and widening working-capital pressure.A33
H1 2024 - Sterilisation expansion continued as lower revenue, a net loss and tight liquidity shaped FY2024.A33
H2 2024 - Sterilisation growth plans amid a S$566k loss, negative working capital and covenant risk.A33
H1 2025 - Revenue fell 47% amid Indonesian headwinds, with liquidity and covenant risks still acute.A33
Q1 2026 - Sterilisation rebounded in 2Q, but liquidity pressure and a loan covenant breach persist.A33
H1 2026